Efficacy of tandem high-dose chemotherapy and autologous stem cell rescue in patients over 1 year of age with stage 4 neuroblastoma: The Korean society of pediatric hematology-oncology experience over 6 years (2000-2005)

Ki Woong Sung, Hyo Seop Ahn, Bin Cho, Yong Mook Choi, Nack Gyun Chung, Tai Ju Hwang, Ho Joon Im, Dae Chul Jeong, Hyoung Jin Kang, Hong Hoe Koo, Hoon Kook, Hack Ki Kim, Chuhl Joo Lyu, Jong Jin Seo, Hee Young Shin, Keon Hee Yoo, Sung Chul Won, Kun Soo Lee

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The efficacy of tandem high-dose chemotherapy and autologous stem cell rescue (HDCT/ASCR) was investigated in patients with high-risk neuroblastoma. Patients over 1 yr of age who were newly diagnosed with stage 4 neuroblastoma from January 2000 to December 2005 were enrolled in The Korean Society of Pediatric Hematology-Oncology registry. All patients who were assigned to receive HDCT/ASCR at diagnosis were retrospectively analyzed to investigate the efficacy of single or tandem HDCT/ASCR. Seventy and 71 patients were assigned to receive single or tandem HDCT/ASCR at diagnosis. Fifty-seven and 59 patients in the single or tandem HDCT group underwent single or tandem HDCT/ASCR as scheduled. Twenty-four and 38 patients in the single or tandem HDCT group remained event free with a median follow-up of 56 (24-88) months. When the survival rate was analyzed according to intent-to-treat at diagnosis, the probability of the 5-yr event-free survival±95% confidence intervals was higher in the tandem HDCT group than in the single HDCT group (51.2±12.4% vs. 31.3±11.5%, P=0.030). The results of the present study demonstrate that the tandem HDCT/ASCR strategy is significantly better than the single HDCT/ASCR strategy for improved survival in the treatment of high-risk neuroblastoma patients.

Original languageEnglish
Pages (from-to)691-697
Number of pages7
JournalJournal of Korean Medical Science
Volume25
Issue number5
DOIs
StatePublished - 1 May 2010

Fingerprint

Hematology
Neuroblastoma
Stem Cells
Pediatrics
Drug Therapy
Registries
Survival Rate
Confidence Intervals
Survival

Keywords

  • Autologous
  • High-dose chemotherapy
  • Neuroblastoma
  • Transplantation

Cite this

Sung, Ki Woong ; Ahn, Hyo Seop ; Cho, Bin ; Choi, Yong Mook ; Chung, Nack Gyun ; Hwang, Tai Ju ; Im, Ho Joon ; Jeong, Dae Chul ; Kang, Hyoung Jin ; Koo, Hong Hoe ; Kook, Hoon ; Kim, Hack Ki ; Lyu, Chuhl Joo ; Seo, Jong Jin ; Shin, Hee Young ; Yoo, Keon Hee ; Won, Sung Chul ; Lee, Kun Soo. / Efficacy of tandem high-dose chemotherapy and autologous stem cell rescue in patients over 1 year of age with stage 4 neuroblastoma : The Korean society of pediatric hematology-oncology experience over 6 years (2000-2005). In: Journal of Korean Medical Science. 2010 ; Vol. 25, No. 5. pp. 691-697.
@article{a3c486b743954e539a37228d7c3d2466,
title = "Efficacy of tandem high-dose chemotherapy and autologous stem cell rescue in patients over 1 year of age with stage 4 neuroblastoma: The Korean society of pediatric hematology-oncology experience over 6 years (2000-2005)",
abstract = "The efficacy of tandem high-dose chemotherapy and autologous stem cell rescue (HDCT/ASCR) was investigated in patients with high-risk neuroblastoma. Patients over 1 yr of age who were newly diagnosed with stage 4 neuroblastoma from January 2000 to December 2005 were enrolled in The Korean Society of Pediatric Hematology-Oncology registry. All patients who were assigned to receive HDCT/ASCR at diagnosis were retrospectively analyzed to investigate the efficacy of single or tandem HDCT/ASCR. Seventy and 71 patients were assigned to receive single or tandem HDCT/ASCR at diagnosis. Fifty-seven and 59 patients in the single or tandem HDCT group underwent single or tandem HDCT/ASCR as scheduled. Twenty-four and 38 patients in the single or tandem HDCT group remained event free with a median follow-up of 56 (24-88) months. When the survival rate was analyzed according to intent-to-treat at diagnosis, the probability of the 5-yr event-free survival±95{\%} confidence intervals was higher in the tandem HDCT group than in the single HDCT group (51.2±12.4{\%} vs. 31.3±11.5{\%}, P=0.030). The results of the present study demonstrate that the tandem HDCT/ASCR strategy is significantly better than the single HDCT/ASCR strategy for improved survival in the treatment of high-risk neuroblastoma patients.",
keywords = "Autologous, High-dose chemotherapy, Neuroblastoma, Transplantation",
author = "Sung, {Ki Woong} and Ahn, {Hyo Seop} and Bin Cho and Choi, {Yong Mook} and Chung, {Nack Gyun} and Hwang, {Tai Ju} and Im, {Ho Joon} and Jeong, {Dae Chul} and Kang, {Hyoung Jin} and Koo, {Hong Hoe} and Hoon Kook and Kim, {Hack Ki} and Lyu, {Chuhl Joo} and Seo, {Jong Jin} and Shin, {Hee Young} and Yoo, {Keon Hee} and Won, {Sung Chul} and Lee, {Kun Soo}",
year = "2010",
month = "5",
day = "1",
doi = "10.3346/jkms.2010.25.5.691",
language = "English",
volume = "25",
pages = "691--697",
journal = "Journal of Korean medical science",
issn = "1011-8934",
publisher = "Korean Academy of Medical Science",
number = "5",

}

Efficacy of tandem high-dose chemotherapy and autologous stem cell rescue in patients over 1 year of age with stage 4 neuroblastoma : The Korean society of pediatric hematology-oncology experience over 6 years (2000-2005). / Sung, Ki Woong; Ahn, Hyo Seop; Cho, Bin; Choi, Yong Mook; Chung, Nack Gyun; Hwang, Tai Ju; Im, Ho Joon; Jeong, Dae Chul; Kang, Hyoung Jin; Koo, Hong Hoe; Kook, Hoon; Kim, Hack Ki; Lyu, Chuhl Joo; Seo, Jong Jin; Shin, Hee Young; Yoo, Keon Hee; Won, Sung Chul; Lee, Kun Soo.

In: Journal of Korean Medical Science, Vol. 25, No. 5, 01.05.2010, p. 691-697.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Efficacy of tandem high-dose chemotherapy and autologous stem cell rescue in patients over 1 year of age with stage 4 neuroblastoma

T2 - The Korean society of pediatric hematology-oncology experience over 6 years (2000-2005)

AU - Sung, Ki Woong

AU - Ahn, Hyo Seop

AU - Cho, Bin

AU - Choi, Yong Mook

AU - Chung, Nack Gyun

AU - Hwang, Tai Ju

AU - Im, Ho Joon

AU - Jeong, Dae Chul

AU - Kang, Hyoung Jin

AU - Koo, Hong Hoe

AU - Kook, Hoon

AU - Kim, Hack Ki

AU - Lyu, Chuhl Joo

AU - Seo, Jong Jin

AU - Shin, Hee Young

AU - Yoo, Keon Hee

AU - Won, Sung Chul

AU - Lee, Kun Soo

PY - 2010/5/1

Y1 - 2010/5/1

N2 - The efficacy of tandem high-dose chemotherapy and autologous stem cell rescue (HDCT/ASCR) was investigated in patients with high-risk neuroblastoma. Patients over 1 yr of age who were newly diagnosed with stage 4 neuroblastoma from January 2000 to December 2005 were enrolled in The Korean Society of Pediatric Hematology-Oncology registry. All patients who were assigned to receive HDCT/ASCR at diagnosis were retrospectively analyzed to investigate the efficacy of single or tandem HDCT/ASCR. Seventy and 71 patients were assigned to receive single or tandem HDCT/ASCR at diagnosis. Fifty-seven and 59 patients in the single or tandem HDCT group underwent single or tandem HDCT/ASCR as scheduled. Twenty-four and 38 patients in the single or tandem HDCT group remained event free with a median follow-up of 56 (24-88) months. When the survival rate was analyzed according to intent-to-treat at diagnosis, the probability of the 5-yr event-free survival±95% confidence intervals was higher in the tandem HDCT group than in the single HDCT group (51.2±12.4% vs. 31.3±11.5%, P=0.030). The results of the present study demonstrate that the tandem HDCT/ASCR strategy is significantly better than the single HDCT/ASCR strategy for improved survival in the treatment of high-risk neuroblastoma patients.

AB - The efficacy of tandem high-dose chemotherapy and autologous stem cell rescue (HDCT/ASCR) was investigated in patients with high-risk neuroblastoma. Patients over 1 yr of age who were newly diagnosed with stage 4 neuroblastoma from January 2000 to December 2005 were enrolled in The Korean Society of Pediatric Hematology-Oncology registry. All patients who were assigned to receive HDCT/ASCR at diagnosis were retrospectively analyzed to investigate the efficacy of single or tandem HDCT/ASCR. Seventy and 71 patients were assigned to receive single or tandem HDCT/ASCR at diagnosis. Fifty-seven and 59 patients in the single or tandem HDCT group underwent single or tandem HDCT/ASCR as scheduled. Twenty-four and 38 patients in the single or tandem HDCT group remained event free with a median follow-up of 56 (24-88) months. When the survival rate was analyzed according to intent-to-treat at diagnosis, the probability of the 5-yr event-free survival±95% confidence intervals was higher in the tandem HDCT group than in the single HDCT group (51.2±12.4% vs. 31.3±11.5%, P=0.030). The results of the present study demonstrate that the tandem HDCT/ASCR strategy is significantly better than the single HDCT/ASCR strategy for improved survival in the treatment of high-risk neuroblastoma patients.

KW - Autologous

KW - High-dose chemotherapy

KW - Neuroblastoma

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=77955300298&partnerID=8YFLogxK

U2 - 10.3346/jkms.2010.25.5.691

DO - 10.3346/jkms.2010.25.5.691

M3 - Article

C2 - 20436703

AN - SCOPUS:77955300298

VL - 25

SP - 691

EP - 697

JO - Journal of Korean medical science

JF - Journal of Korean medical science

SN - 1011-8934

IS - 5

ER -